Literature DB >> 18493099

Study of the metabolites of bencycloquidium bromide racemate, a novel anticholinergic compound, in rat bile by liquid chromatography-tandem mass spectrometry.

Qin Xu1, Li Ding, Wen-Ying Liu, Xiao-Ping Chen, Bu-Ming Liu.   

Abstract

A sensitive and specific liquid chromatographic-electrospray ionization (ESI) tandem ion trap mass spectrometric method has been developed for identification of bencycloquidium bromide (BCQB) and its metabolites in rat bile. Six healthy rats were administrated a single dose (3.0 mg kg(-1)) of BCQB by intraperitoneal (i.p.) injection. The bile were sampled from 0 h to 24 h and purified by using a C(18) solid- phase extraction (SPE) cartridge, then the purified bile samples were separated on a reversed-phase C(18) column using acetonitrile/40 mM ammonium acetate buffer (containing 0.1% formic acid) as mobile phase at gradient elution and detected by an on-line MS(n) detector. Identification and structural elucidation of the metabolites were performed by comparing the changes in molecular weight (Deltam) and full scan MS(n) spectra with those of the parent drug. Eight metabolites (such as hydroxylated and oxidized metabolites) and the parent drug were found in rat bile. Eight metabolites of BCQB were identified and hydroxylated metabolites were the major metabolites. The metabolic pathways of BCQB in vivo are proposed for the first time.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18493099     DOI: 10.1255/ejms.909

Source DB:  PubMed          Journal:  Eur J Mass Spectrom (Chichester)        ISSN: 1469-0667            Impact factor:   1.067


  2 in total

1.  In vitro metabolism of bencycloquidium bromide and its inhibitory effects on human P450 isoenzymes: implication of CYP2D6, CYP2C19 and CYP3A4/5.

Authors:  Janvier Engelbert Agbokponto; Lingling Zhang; Linlin Hu; Hao Feng; Li Ding
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-11-26       Impact factor: 2.441

2.  Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.

Authors:  Luning Sun; Li Ding; Yongqing Wang; Wenjia Zhou; Zhengyu Yan; Weilin Sun; Hongwen Zhang; Ning Ou; Xiaoping Chen
Journal:  Drugs R D       Date:  2012-03-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.